Recombinant Enterococcus Vaccine Antigens for Antibiotic-Resistant Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a preventative or therapeutic vaccine against Enterococcus infections, particularly caused by Enterococcus faecalis, due to high antibiotic resistance and significant health and economic burdens from root canal failures and other opportunistic infections, with no existing effective vaccine available.
Innovation Solution
Development of an immunogenic composition comprising recombinant Enterococcus polypeptide antigens, such as Ace, AdcA, AdcAII, EbpA, EfaA, and Esp, to induce a protective immune response against Enterococcus bacteria, including Enterococcus faecalis, faecium, and durans strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat Enterococcus infections, then infection rates can be reduced, but antibiotic resistance develops making treatments ineffective
Solution Approach 1:
The patent introduces a vaccine as an intermediary preventive measure that stimulates the immune system to produce antibodies against Enterococcus bacteria. This mediator approach allows the body's own immune system to combat the infection rather than relying on external antibiotics, thereby avoiding the development of antibiotic resistance while maintaining treatment effectiveness.
Solution Approach 2:
The vaccine provides preliminary protective action by pre-stimulating the immune system before infection occurs. Through immunization with recombinant polypeptide antigens, the body develops immunity in advance, preventing the need for antibiotic intervention and thus preventing resistance development before it can occur.
2Adaptability or versatility
If no vaccine is available, then current treatment options remain limited to antibiotics, but this leads to high failure rates and economic burden
Solution Approach 1:
The patent segments the protective function into multiple components by using combinations of different recombinant polypeptide antigens (Ace, AdcA, AdcAII, EbpA, EfaA, Esp). This segmented approach allows for targeted immunity against different virulence factors of Enterococcus, creating versatile treatment options that can be tailored to specific infection risks and improving overall reliability of prevention.
3Object-affected harmful factors
If Enterococcus infections are left untreated, then antibiotic resistance cannot develop, but infection causes significant health complications and economic burden
Solution Approach 1:
The patent converts the harmful presence of Enterococcus bacteria, which normally causes infection and complications, into a beneficial preventive target. By identifying specific bacterial polypeptides as antigens and using them in vaccines, the harmful pathogen itself becomes the basis for creating protective immunity, transforming the threat into a solution that prevents both infection complications and antibiotic resistance.
Data Source
AI summary
The present disclosure provides immunogenic compositions comprising at least one recombinant polypeptide antigen derived from an Enterococcus bacterium (e.g., E. faecalis, E. faecium, E. durans). The disclosure further provides methods, and uses of the immunogenic compositions, for protecting or treating a subject from infection by an Enterococcus bacterium. Such infections may cause, or worsen, conditions such as root canal failure, endocarditis, bacteremia, urinary tract infections, prostatitis, intraabdominal infection, cellulitis, dysbiotic gastrointestinal tract, prosthetic joint infection, or wound infections.